Sponsor of the Day:
Jerkmate
https://www.sanofi.com/en/media-room/press-releases/2026/2026-03-24-06-00-00-3260948
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe...
press release sanofidupixent approvedfirst targetedjapanmedicine
https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-24-14-30-00-3243732
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine...
Sanofi and Regeneron s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6...
press release sanofidupixent approvedusfirstmedicine
https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-13-05-00-00-3272182
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to...
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU...
press release sanofidupixent approvedfirst targetedeumedicine